Schrödinger (SDGR) Stock Surges 60% but $37 Resistance Could Test the Rally as Mixed Fundamentals Raise Fresh Risks

Schrodinger Inc (NASDAQ: SDGR) launched Tectora, a biotech firm focused on immunology and inflammation, backed by a $55M Series A funding. SDGR's P/S ratio is 7.7x, below its 10.3x historical median, suggesting cautious growth expectations. Its GF Score™ is 72/100, indicating moderate fundamental strength with notable valuation and momentum but weak profitability. Insider activity shows $1.4M in selling over the past year, while institutional sentiment is mixed.

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

Schrödinger (SDGR) reported Q2 2026 revenue of $58.89M, turning from a prior-year loss to net income of $5.98M, and filed a $46.95M shelf registration for 3,000,000 shares tied to its ESOP. Bristol Myers Squibb said it will deploy Schrödinger’s agentic AI co-scientist Bunsen across its research organization, expanding their collaboration.

Schrodinger, Inc. (SDGR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Schrödinger Reports Second Quarter 2026 Financial Results Second Quarter ACV of $30 Million, Representing 27% Growth Launched Early Access Version of Bunsen, A New Agentic AI Co-Scientist for Molecular Discovery New York, August 5, 2026 – Schrödinger, Inc. (Nasdaq: S

Samsung Electronics (005930.KS) and SK hynix (000660.KS) saw their worst weekly share price drops since 2008, driven by heavy foreign selling. Samsung fell 17.8% to 215,500 won, while SK hynix dropped 24.3% to 1.272 million won. Foreign investors sold 3.4763 trillion won and 5.3565 trillion won of their shares, respectively. Analysts are divided on future prospects, with some citing strong earnings and others warning of continued volatility.

Elon Musk's net worth fell by $20 billion, aligning with a 1.3% decline in Tesla shares. The drop followed the unveiling of the experimental Tesla Roadster, which impressed investors less than Musk. Tesla's year-to-date market fall is now 17%. The Roadster's production is delayed to 2028, and Tesla's focus on high-end models contrasts with rivals' mass-market strategies. Tesla's Q3 results will be scrutinized for delivery numbers and margins.